LRMR logo

Larimar Therapeutics, Inc. Stock Price

NasdaqGM:LRMR Community·US$479.9m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 13 Fair Values set on narratives written by author

LRMR Share Price Performance

US$4.62
2.47 (114.88%)
US$4.62
2.47 (114.88%)
Price US$4.62

LRMR Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
0 Rewards

Larimar Therapeutics, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$165.7m

Other Expenses

-US$165.7m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-1.59
0%
0%
0%
View Full Analysis

About LRMR

Founded
n/a
Employees
71
CEO
Carole Ben-Maimon
WebsiteView website
www.larimartx.com

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Recent LRMR News & Updates

Recent updates

No updates